

CLIENT CHOICE – LESSONS AND TOOLS FOR PROMOTING CLIENT CHOICE FROM A GLOBAL STUDY INTO LONG ACTING DEPOT BUPRENORPHINE IN LOW AND MIDDLE INCOME COUNTRIES

Speakers/Facilitators:

Southwell Mat¹, Green Kim², Parhomenko Velta³, Madden Annie⁴, Clark Nicolas⁵

¹ Coact Technical Support

² PATH

³ Club Eney

⁴ International Network of People who Use Drugs (INPUD)

⁵ Royal Melbourne Hospital

Biographies

Mat Southwell is Managing and Technical Director of Coact Technical Support. Mat developed the client materials and peer education intervention for the LADB study.

Dr Kim Green is Global Director for Primary Health Care for PATH. Kim is the Principal Investigator for the LADB study.

Velta Parhomenko is the Executive Director of Club Eney a community-led harm reduction service in Ukraine. Velta is the community narrator of the LADB Client Video.

Dr Annie Madden is the Unitaids Project Lead for the International Network of People Who Use Drugs (INPUD) and has led on the values and preferences research.

Dr Nicolas Clark is an Associate Professor at the Royal Melbourne Hospital. He has been PATH and Frontline AIDS' medical advisor on the LADB study.

Background and aims:

Opioid agonist maintenance treatment are effective medications for opioid dependence that reduce the risk of HIV/HCV acquisition, lower the risk of opioid overdose, and facilitate access to wider health and social care. Methadone and sub-lingual buprenorphine are becoming more available in low and middle income countries (LMIC) to support people with opioid dependence. Now Long Acting Depot Buprenorphine (LADB) is being made available in 8 LMIC as part of a global study funded by Unitaids.

The monthly depot injection of buprenorphine offers greater freedom from clinic attendance, releasing time to focus time on family, work and/or education. People with opioid dependence are best able to make informed choices about their preferred medication when they are well informed, confident in their rights, and have a strong partnership with their prescriber. The LADB study has supported the development of a comprehensive toolkit that can be used to build client literacy and choice supporting treatment quality and retention.

Description of workshop:

The workshop will provide a practical discussion of the importance of promoting client literacy and choice with OAMT based on the tools and lessons developed for the LADB study. Both peer educator and prescriber approaches to supporting client literacy and choice will be discussed in a panel discussion. Participants will review various case studies using a tool from the LADB study to help match clients to different OAMT medications. Participants will leave with a strengthened understanding of OAMT literacy and choice.

Methods and format:

- Facilitator welcome and outline of workshop

-
- Panel discussion about the LADB study and the materials and interventions that support client literacy and choice
 - Viewing of the LADB Client Video
 - Building client and prescriber confidence around informed choice in OAMT
 - Case studies exploring client literacy and choice

Ideal number and type of delegate, how many people can the workshop accommodate and who is this workshop designed for?

60+ people who are on OAMT or working in OAMT services or otherwise stakeholders in the OAMT system.

Disclosure of Interest Statement:

- All the workshop leaders are part of the Unitaid funded study into London Acting Deport Buprenorphine in Low and Middle Income Countries
- Mat Southwell has worked for drug user organisations that have received unrestricted educational grants from OAMT pharmaceutical companies to support client literacy and choice.